1-(4-氟苯基)-5-甲基-1H-1,2,3-噻唑-4-羧酸 | 887035-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-氟苯基)-5-甲基-1H-1,2,3-噻唑-4-羧酸
• 中文别名: 1-(4-氟苯基)-5-甲基-1h-[1,2,3]三唑-4-羧酸
• 英文名称: 1-(4-fluoro-phenyl)-5-methyl-1H-[1,2,3]triazole-4-carboxylic acid
• 英文别名: 1-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylic acid；1-(4-fluorophenyl)-5-methyltriazole-4-carboxylic acid
• CAS: 887035-89-4
• 化学式: C₁₀H₈FN₃O₂
• mdl: MFCD07397776
• 分子量: 221.191
• InChiKey: AEXWTPJOQWLAFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(4-Fluoro-phenyl)-5-methyl-1h-[1,2,3]triazole-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(4-Fluoro-phenyl)-5-methyl-1h-[1,2,3]triazole-4-carboxylic acid
CAS number: 887035-89-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H8FN3O2
Molecular weight: 221.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-氟苯基)-5-甲基-1H-1,2,3-噻唑-4-羧酸 在 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.52h， 生成 N-(tert-butyl)-1-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide
  参考文献：
  名称：

  1H-1,2,3-triazole-4-carbonitriles 的合成作为有前景的 2-(triazol-4-yl)-thieno[2,3-d] 嘧啶候选药物的构建单元

  摘要：

  摘要 已经开发了导致功能化的 1 H -1,2,3-三唑-4-腈的新合成路线。一组 1-芳基-5-甲基-1 H -1,2,3-三唑-4-甲腈从容易获得的起始 1 H -1,2,3-三唑-4-羧酸中以高收率获得几种合成方案。合成的 1 H -1,2,3-三唑-4-腈被认为是一种简单有效的制备 2-三唑-4-基-噻吩并[2,3- d ]嘧啶的有前途的前体。这种方法允许创建用于抗癌药物发现的广泛组合库。

  DOI：

  10.1080/00397911.2021.1966041
• 作为产物：
  描述：

  1-叠氮基-4-氟苯 在 水 、 二乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 36.0h， 生成 1-(4-氟苯基)-5-甲基-1H-1,2,3-噻唑-4-羧酸
  参考文献：
  名称：

  PROTEOSTASIS REGULATORS

  摘要：

  本发明涉及具有化学式(Ia-Ie)、(II)、(IIIa-IIId)、(IVa-IVc)、(Va-Vb)、(VIa-VIe)、(VII)、(VIIIa-VIIIc)和(IX)的化合物，以及这些化合物的药用可接受盐、前药和溶剂合物，以及这些化合物的任何组合物，并且用于治疗与蛋白质稳态功能紊乱相关的疾病的方法，包括有效量的这些化合物。

  公开号：

  US20120316193A1

文献信息

• [EN] TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY<br/>[FR] DÉRIVÉS AMIDES DE TRIAZOLE DESTINÉS À ÊTRE UTILISÉS EN THÉRAPIE
  申请人：GLAXO GROUP LTD

  公开号：WO2009115486A1

  公开（公告）日：2009-09-24

  The invention relates to triazole amide derivatives of formula (I) for use in therapy, in particular for treating diseases and conditions mediated by antagonism of the mGluR5 receptor, in particular substance related disorders. The invention also relates to certain novel derivatives. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

  该发明涉及公式（I）的三唑酰胺衍生物，用于治疗特定由mGluR5受体拮抗介导的疾病和症状，特别是物质相关障碍。该发明还涉及某些新颖的衍生物。此外，该发明涉及含有这些衍生物的组合物以及它们的制备方法。
• [EN] ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ACYLPIPÉRAZINE À TITRE DE BLOQUEURS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2012020567A1

  公开（公告）日：2012-02-16

  The present invention relates to acyl piperazine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及酰基哌嗪衍生物，具有阻断电压门控钠通道（如TTX-S通道）活性的特性，可用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的疾病中使用这些化合物和组合物。
• Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors
  作者：Qidong Tang、Linxiao Wang、Yayi Tu、Wufu Zhu、Rong Luo、Qidong Tu、Ping Wang、Chunjiang Wu、Ping Gong、Pengwu Zheng

  DOI：10.1016/j.bmcl.2016.02.059

  日期：2016.4

  A series of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety were designed, synthesized, and evaluated for their c-Met kinase inhibitory activities and antiproliferative activities against 4 cancer cell lines (HT-29, A549, MCF-7, and PC-3) in vitro. Most compounds showed moderate to excellent potency, with the most promising analog 34 showing a c-Met IC50 value of 1.68 nM. Structure–activity

  设计，合成了一系列带有1,2,3-三唑部分的新型吡咯并[2,3-b]吡啶衍生物，并评估了它们对4种癌细胞系（c-HT-29）的c-Met激酶抑制活性和抗增殖活性，A549，MCF-7和PC-3）。大多数化合物显示出中等至出色的效价，最有前途的类似物34的c-Met IC 50值为1.68 nM。结构-活性关系研究表明，需要吸电子基团（X = CF 3，R 1  = F，R 2  = 4-F），以适当程度降低5-原子连接基上的较高电子密度，从而改善5-氟原子。抑制活性。
• Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors
  作者：Linxiao Wang、Xiaobo Liu、Yongli Duan、Xiaojing Li、Bingbing Zhao、Caolin Wang、Zhen Xiao、Pengwu Zheng、Qidong Tang、Wufu Zhu

  DOI：10.1111/cbdd.13192

  日期：2018.7

  2.90 ± 0.43 μm, respectively. Secondly, the SARs and docking studies indicated that the in vitro antitumor activity of pyrrolo[2,3‐d]pyrimidine derivatives bearing 1,2,3‐triazole moiety was superior to the pyrazolo[3,4‐d]pyrimidine derivatives bearing 1,2,3‐triazole moiety. Thirdly, three selected compounds (16d, 18d, and 20d) were further evaluated for inhibitory activity against the c‐Met kinase,

  设计并合成了带有1,2,3-三唑部分的6个吡咯并[2,3- d ]嘧啶和吡唑并[3,4- d ]嘧啶衍生物，并进行了一些生物评价。其结果，四个点可以概括：首先，一些化合物的显示出优异的细胞毒性活性和选择性与IC 50中的个位数μ值米水平。特别地，最有前途的化合物16D呈等活性铅化合物foretinib针对A549，HepG2细胞，和MCF-7细胞系，与IC 50为4.79±0.82的值，2.03±0.39，和2.90±0.43μ米， 分别。其次，SAR和对接研究表明，带有1,2,3-三唑部分的吡咯并[2,3- d ]嘧啶衍生物的体外抗肿瘤活性优于带有1的吡唑并[3,4- d ]嘧啶衍生物。 ，2,3-三唑部分 第三，进一步评估了三种选定的化合物（16d，18d和20d）对c-Met激酶的抑制活性，并且16d可以通过基于酶的选择性实验选择性地抑制c-Met激酶。而且16d可以通过a啶橙染色和
• TRIAZOLE AMIDE DERIVATIVES FOR USE IN THERAPY
  申请人：Garzya Vincenzo

  公开号：US20110065725A1

  公开（公告）日：2011-03-17

  The invention relates to triazole amide derivatives of formula (I) for use in therapy, in particular for treating diseases and conditions mediated by antagonism of the mGluR 5 receptor, in particular substance related disorders. The invention also relates to certain novel derivatives. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

  本发明涉及式（I）的三唑酰胺衍生物，用于治疗疾病和条件，特别是通过拮抗mGluR5受体介导的物质相关障碍。本发明还涉及某些新颖的衍生物。此外，本发明涉及含有这些衍生物的组合物和它们的制备方法。